STOCK TITAN

Kronos Bio, Inc. - KRON STOCK NEWS

Welcome to our dedicated page for Kronos Bio news (Ticker: KRON), a resource for investors and traders seeking the latest updates and insights on Kronos Bio stock.

Kronos Bio, Inc. (Nasdaq: KRON) is a clinical-stage biopharmaceutical company committed to transforming patient outcomes through the discovery and development of novel cancer therapeutics. With a focus on modulating historically challenging cancer targets, the company leverages industry-leading high-throughput screening strategies and its proprietary small molecule microarray (SMM) platform. Kronos Bio's core business revolves around developing therapies that target the deregulated transcription processes fundamental to many cancers.

The company's most prominent projects include KB-0742, an inhibitor of CDK9, which has shown promising anti-tumor activity and a manageable safety profile in early trials involving patients with transcriptionally addicted solid tumors. The ongoing phase 1/2 trial has recently escalated dosing to 80 mg, with expansion cohort data anticipated in mid-2024.

Another key development is KB-9558, targeting the lysine acetyltransferase (KAT) domain of p300, a crucial component in the IRF4 transcription regulatory network. This molecule is currently in IND-enabling studies, expected to be completed by Q4 2024. KB-9558 aims to provide a novel treatment for multiple myeloma, a disease driven by IRF4, for which existing therapies are not curative.

Despite deciding not to advance the phase 1b/2 trial of lanraplenib in combination with gilteritinib for FLT3-mutated relapsed/refractory acute myeloid leukemia (AML) to phase 2, Kronos Bio remains open to further developing lanraplenib with a partner. The company emphasizes its strong biological rationale and engagement in target modulation in AML, even though it did not observe sufficient response in the study population.

Under the leadership of President and CEO Dr. Norbert Bischofberger, Kronos Bio continues to innovate, focusing on mapping transcription regulatory networks (TRNs) to identify and target key modulators, ultimately leading to the development of novel drug candidates. The company's latest structural and leadership changes are designed to streamline operations and ensure efficient delivery on business objectives.

Kronos Bio is based in San Mateo, Calif., with a research facility in Cambridge, Mass. For more information, visit https://www.kronosbio.com/ or follow the company on LinkedIn.

Rhea-AI Summary
Kronos Bio, Inc. (Nasdaq: KRON) will participate in the 44th Annual Cowen Health Care Conference, with the CEO joining a panel discussion on Novel Oncology Targets. The event will take place from March 4-6, 2024, in Boston, Massachusetts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
none
-
Rhea-AI Summary
Kronos Bio, Inc. has announced a streamlined leadership structure, eliminating three executive officer roles and appointing a new Executive Leadership team. The company aims to focus on pipeline advancement and align with current operating needs. The new leadership structure includes a Senior Vice President for Research and Development, a Senior Vice President for Clinical Development, a Senior Vice President for Corporate Strategy and Portfolio Management, and a Senior Vice President for Corporate Operations and Legal. The changes are designed to optimize resources and efficiently deliver on business objectives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
none
-
Rhea-AI Summary
Kronos Bio, Inc. (Nasdaq: KRON) provides an update on its pipeline, including the completion of the phase 1b portion of the lanraplenib study, the designation of a new development candidate KB-9558, and the progress of its first development candidate KB-0742. The company also maintains its expected cash runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.01%
Tags
none
Rhea-AI Summary
Kronos Bio, Inc. (Nasdaq: KRON) announced the participation of key executives in a fireside chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference. The event will be held on December 6, 2023, at 11:00 a.m. ET, with a live audio webcast available on the company's website. The participation of Dr. Jorge DiMartino and Dr. Charles Lin signifies the company's commitment to advancing precision oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
none
-
Rhea-AI Summary
Kronos Bio, Inc. (KRON) to participate in fireside chat at 35th Annual Piper Sandler Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
none
-
Rhea-AI Summary
Kronos Bio, Inc. (Nasdaq: KRON) reported positive preliminary data from the Phase 1 dose escalation portion of the KB-0742 study at AACR-NCI-EORTC and CTOS conferences. This data showed on-mechanism, single agent anti-tumor activity and a manageable safety profile in pre-treated patients with transcriptionally addicted solid tumors. The company also announced a plan to optimize resource allocation, restructure, and contain costs, extending its cash runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
Rhea-AI Summary
Kronos Bio, Inc. announces a plan to optimize resource allocation and restructure in light of positive clinical data from its Phase 1/2 study of KB-0742. The company will focus on exploring KB-0742's potential, advancing lanraplenib development, and maturing projects. Restructuring efforts include a 19% reduction in force and are expected to extend the company's cash runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15%
Tags
-
Rhea-AI Summary
Kronos Bio, Inc. presented positive preliminary data from the phase 1 dose escalation portion of the ongoing KB-0742 study at the Connective Tissue Oncology Society annual meeting. The data showed on-mechanism, single agent anti-tumor activity and a manageable safety profile in heavily pre-treated patients with transcriptionally addicted solid tumors. Preclinical studies also demonstrated KB-0742's activity in models for rhabdomyosarcoma and Ewing sarcoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.1%
Tags
-
Rhea-AI Summary
Kronos Bio, Inc. will present positive preliminary data from the ongoing KB-0742 study at the Connective Tissue Oncology Society annual meeting. The data includes clinical data presented at a previous conference and provides a better understanding of the observed anti-tumor activity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.98%
Tags
conferences clinical trial
Rhea-AI Summary
Kronos Bio announces positive preliminary data from Phase 1 trial of KB-0742 for treating transcriptionally addicted solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.65%
Tags

FAQ

What is the current stock price of Kronos Bio (KRON)?

The current stock price of Kronos Bio (KRON) is $0.9579 as of December 20, 2024.

What is the market cap of Kronos Bio (KRON)?

The market cap of Kronos Bio (KRON) is approximately 57.9M.

What is Kronos Bio, Inc.'s core business focus?

Kronos Bio focuses on discovering and developing novel cancer therapeutics targeting deregulated transcription processes.

What are the key development projects at Kronos Bio?

Currently, KB-0742 and KB-9558 are key projects, targeting CDK9 in solid tumors and the KAT domain of p300 in multiple myeloma, respectively.

Where is Kronos Bio, Inc. headquartered?

Kronos Bio is headquartered in San Mateo, California, with a research facility in Cambridge, Massachusetts.

What is the latest update on KB-0742?

KB-0742 has shown promising anti-tumor activity and is currently in the dose escalation phase of its phase 1/2 trial, with data expected in mid-2024.

Why did Kronos Bio decide not to proceed with lanraplenib's phase 2 trial?

The decision was based on insufficient patient response in the phase 1b trial for FLT3-mutated relapsed/refractory AML, though the company is open to further developing lanraplenib with a partner.

What is KB-9558 and its purpose?

KB-9558 targets the KAT domain of p300, a crucial element in the IRF4 transcription regulatory network, aiming to provide a novel treatment for multiple myeloma.

Who is the CEO of Kronos Bio, Inc.?

Dr. Norbert Bischofberger is the President and Chief Executive Officer of Kronos Bio.

What are Kronos Bio's proprietary platforms?

Kronos Bio utilizes its small molecule microarray (SMM) platform for high-throughput screening of chemical modulators in cancer research.

How can I get more information about Kronos Bio?

You can visit their website at https://www.kronosbio.com/ or follow the company on LinkedIn for more updates.

What recent structural changes have occurred at Kronos Bio?

Kronos Bio recently eliminated three executive officer roles and appointed a new executive leadership team to streamline operations and advance their pipeline.

Kronos Bio, Inc.

Nasdaq:KRON

KRON Rankings

KRON Stock Data

57.93M
42.82M
26.9%
32.67%
0.88%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN MATEO